Live from the NIH registry
Studies recruiting near Salem right now
Top 25 of 111 recruiting studies, sorted by proximity — each links to its official registry page
The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease
Aortoiliac Occlusive Disease, Peripheral Arterial Disease
N/A
Interventional 244 participants sought
Providence Heart & Vascular Institute — Wilsonville, Oregon (28.7 mi)
· Sponsor: W.L.Gore & Associates
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Non-small Cell Lung Cancer (NSCLC)
Phase 3
Interventional 614 participants sought
Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0117) — Corvallis, Oregon (27.4 mi)
· Sponsor: Merck Sharp & Dohme LLC
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
Sepsis, Acute Kidney Injury
Phase 2
Interventional 124 participants sought
Research Site — Corvallis, Oregon (27.4 mi)
· Sponsor: AstraZeneca
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
HR+/HER2- Breast Cancer
Phase 3
Interventional 1,056 participants sought
Oregon Oncology Specialists — Salem, Oregon (1.5 mi)
· Sponsor: BeOne Medicines
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
Phase 3
Interventional 1,160 participants sought
Research Site — Salem, Oregon (1.5 mi)
· Sponsor: AstraZeneca
Virtual Mindful After Cancer (MAC) Intervention to Promote Sexual Health for Breast and Gynecologic Cancer Survivors
Gynecologic Cancers, Breast Cancer
Phase 1
Interventional 60 participants sought
Samaritan Pastega Regional Cancer Center — Corvallis, Oregon (27.4 mi)
· Sponsor: Oregon State University
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Malignant Solid Neoplasm
N/A
Observational 2,062 participants sought
Providence Newberg Medical Center — Newberg, Oregon (26.2 mi)
· Sponsor: SWOG Cancer Research Network
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Metastatic Colorectal Cancer
Phase 1
Interventional 542 participants sought
Hematology Oncology Salem — Salem, Oregon (1.5 mi)
· Sponsor: Hoffmann-La Roche
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Phase 3
Interventional 3,680 participants sought
Providence Newberg Medical Center — Newberg, Oregon (26.2 mi)
· Sponsor: National Cancer Institute (NCI)
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
Viral Lung Infection and Acute Respiratory Failure
Phase 3
Interventional 3,527 participants sought
Research Site — Corvallis, Oregon (27.4 mi)
· Sponsor: AstraZeneca
Proximal FEmur Reconstruction or Internal Fixation fOR Metastases (PERFORM) Trial
Metastatic Bone Disease
N/A
Interventional 334 participants sought
Good Samaritan Regional Medical Center — Corvallis, Oregon (27.4 mi)
· Sponsor: Michelle Ghert, MD
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia
Phase 3
Interventional 303 participants sought
Providence Newberg Medical Center — Newberg, Oregon (26.2 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma
Phase 2, Phase 3
Interventional 686 participants sought
Providence Newberg Medical Center — Newberg, Oregon (26.2 mi)
· Sponsor: NRG Oncology
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma
Phase 2
Interventional 227 participants sought
Providence Newberg Medical Center — Newberg, Oregon (26.2 mi)
· Sponsor: SWOG Cancer Research Network
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma
Phase 3
Interventional 336 participants sought
Providence Newberg Medical Center — Newberg, Oregon (26.2 mi)
· Sponsor: National Cancer Institute (NCI)
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma
N/A
Observational 800 participants sought
Providence Newberg Medical Center — Newberg, Oregon (26.2 mi)
· Sponsor: University of Rochester
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Miscellaneous Neoplasm, Nos, Non-Neoplastic Condition, Nos
N/A
Interventional 535 participants sought
Providence Newberg Medical Center — Newberg, Oregon (26.2 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features
Phase 3
Interventional 600 participants sought
Providence Newberg Medical Center — Newberg, Oregon (26.2 mi)
· Sponsor: National Cancer Institute (NCI)
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Phase 3
Interventional 1,100 participants sought
Salem Hospital — Salem, Oregon (1.5 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype
Phase 2
Interventional 900 participants sought
Providence Newberg Medical Center — Newberg, Oregon (26.2 mi)
· Sponsor: SWOG Cancer Research Network
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Pancreatic Neoplasm
N/A
Observational 770 participants sought
Providence Newberg Medical Center — Newberg, Oregon (26.2 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Myelodysplastic Syndromes, Acute Myeloid Leukemia
Phase 2, Phase 3
Interventional 316 participants sought
Oregon Oncology Specialists — Salem, Oregon (1.5 mi)
· Sponsor: Taiho Oncology, Inc.
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Phase 3
Interventional 306 participants sought
Providence Newberg Medical Center — Newberg, Oregon (26.2 mi)
· Sponsor: National Cancer Institute (NCI)
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
Colorectal Cancer Stage II, Colorectal Cancer Stage III
Phase 3
Interventional 1,057 participants sought
Providence Newberg Medical Center — Newberg, Oregon (26.2 mi)
· Sponsor: SWOG Cancer Research Network
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
Macular Degeneration, Age-Related Macular Degeneration
Phase 2, Phase 3
Interventional 960 participants sought
Retina Consultants, LLC — Salem, Oregon (1.5 mi)
· Sponsor: EyeBiotech Ltd.